Xechem International Inc. (fka XKEM)

[VERITAS77]

For the below reason alone, the employees best interest are to encourage the completion of the facility and the mass distribution of Nicosan, being important shareholders.

Industry : BiotechnologyEmployees : 78 Exchange : OTC BB

Xechem International, Inc. is a holding company that owns all of the capital stock of Xechem, Inc., a development stage biopharmaceutical company engaged in the research and technology development of generic and drugs from natural sources. Research and development efforts focus principally on antifungal, anticancer, antiviral (including anti-AIDS) and anti-inflammatory compounds, as well as anti-aging and memory enhancing compounds. Xechem is also focusing on phytopharmaceuticals and other technologies for orphan diseases. As of December 31, 2005, the Company's lead project involves the development of a phytopharmaceutical product, NICOSAN/HEMOXIN, which has received United States Food and Drug Administration (FDA)-designated orphan drug status as the first definitive therapy for sickle cell disease (SCD). The development and production of NICOSAN/HEMOXIN is being conducted through Xechem Pharmaceuticals Nigeria Limited (Xechem Nigeria).
IMO if XKEM were to launch a compaign to promote even one single other aspect about their corporation, say anti aging and memory compounds, the pps share could see a dramatic spike.
With the ever increasing demand for the fountain of youth for the older generation (big money) IMO it could be very profitable(revenues) to add interest in this portion of their company.
Every positve PR be it from the company or other reporting agencies adds ongoing interest of the company itself. If they could market such compounds for anti aging and memory (for example) increased awareness and money flow could find its way where it is needed to make XKEM a major player in the market.
LIVE4TRUTH. -VERITAS77